NovoCure Limited (NVCR) Stock Analysis
Range Bound setup
Healthcare · Medical Devices
Sell if holding. Engine safety override at $17.18: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 2.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its... Read more
Sell if holding. Engine safety override at $17.18: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 2.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 51 mid-range, Bollinger mid-band. Score 5.4/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 44d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — NovoCure Limited
Latest news
- NEWS NVCR Director Vernon Anthony Acquires 21,500 Shares April 28 - Meyka — Meyka positive
- NEWS NovoCure Limited (NVCR) Reports Strong Q1 2026 Results and FDA A - GuruFocus — GuruFocus positive
- NEWS Novocure (NVCR) Shares Jump 22% on Strong Q1 Revenue and Raised Outlook - GuruFocus — GuruFocus positive
- NEWS NovoCure (NASDAQ:NVCR) Shares Gap Up - Should You Buy? - MarketBeat — MarketBeat positive
- NEWS NVCR Stock Update: Insights on Current Market Trends - GuruFocus — GuruFocus neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -25.7%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $17.18: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 2.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $16.03. Score 5.4/10, moderate confidence.
Take-profit target: $22.87 (+32.7% upside). Prior stop was $16.03. Stop-loss: $16.03.
Quality below floor (3.9 < 4.0).
NovoCure Limited trades at a P/E of N/A (forward -14.4). TrendMatrix value score: 8.7/10. Verdict: Sell.
13 analysts cover NVCR with a consensus score of 4.1/5. Average price target: $26.
What does NovoCure Limited do?NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating...
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.